245 related articles for article (PubMed ID: 25588772)
1. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
3. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A; Palumbo C; Zamboni S; Mazziotti G; Triggiani L; Zamparini M; Maffezzoni F; Rinaudo L; Bergamini M; Di Meo N; Caramella I; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Berruti A
J Endocrinol Invest; 2024 Feb; 47(2):335-343. PubMed ID: 37458931
[TBL] [Abstract][Full Text] [Related]
5. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
9. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
10. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia during androgen-deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber PR; Tammela TL; Ke C; Leder BZ; Goessl C
J Clin Oncol; 2012 Sep; 30(26):3271-6. PubMed ID: 22649143
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
13. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
14. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
15. Relationship between body composition and bone mass in women.
Khosla S; Atkinson EJ; Riggs BL; Melton LJ
J Bone Miner Res; 1996 Jun; 11(6):857-63. PubMed ID: 8725184
[TBL] [Abstract][Full Text] [Related]
16. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
[TBL] [Abstract][Full Text] [Related]
17. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
18. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
Foulkes SJ; Daly RM; Fraser SF
Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
[TBL] [Abstract][Full Text] [Related]
19. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
Uth J; Hornstrup T; Schmidt JF; Christensen JF; Frandsen C; Christensen KB; Helge EW; Brasso K; Rørth M; Midtgaard J; Krustrup P
Scand J Med Sci Sports; 2014 Aug; 24 Suppl 1():105-12. PubMed ID: 24944134
[TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]